FDA Panel Backs Broader Access to Gray Market Peptides

An FDA advisory panel has voted to recommend easing restrictions on six out of seven popular peptide therapies, a decision that could eventually allow specialized compounding pharmacies in the United States to legally produce them. The July 23-24 vote by the Pharmacy Compounding Advisory Committee (PCAC) marks a pivotal shift in the regulation of compounds that have long circulated through an unregulated gray market, driven in part by the backing of Health and Human Services Secretary Robert F. Kennedy Jr.

The Vote

Over two days of deliberations, the panel weighed evidence for seven synthetic peptides — strings of amino acids that act as signaling molecules in the body — none of which are FDA-approved drugs. By narrow margins, the committee voted to recommend that the FDA add six of them to the Section 503A list, which would permit compounding pharmacies to produce them with a prescription, according to NPR.

The approved peptides and their considered uses are:

• BPC-157 — ulcerative colitis (backed 8-6)
• KPV — wound healing and inflammatory conditions (backed 8-6)
• TB-500 (Thymosin Beta-4) — wound healing (backed 8-6)
• MOTS-c — obesity and osteoporosis (backed 7-5)
• Semax — migraine and cerebral ischemia (backed 8-5)
• Epitalon — insomnia (backed 7-4)

The only compound rejected was Emideltide (DSIP), used for opioid withdrawal and chronic insomnia, which failed by a single vote.

From Gray Market to Regulated Access

Currently, these peptides cannot be legally manufactured in the U.S. except for research purposes. This prohibition, established by the FDA in 2023, has driven consumers to purchase products from overseas suppliers with unknown quality standards, often labeled “for research use only” or “not for human consumption.”

Proponents of the policy shift argue that regulated compounding would improve patient safety. “What we are advocating for is to slow down or shut down the gray and black market and to allow patients to have a safe and effective manufacturing process,” Brigham Buhler, CEO of the telehealth company Ways2Well and an ally of Secretary Kennedy, told the panel.

Scott Brunner, CEO of the Alliance for Pharmacy Compounding, echoed this sentiment, stating that the black and gray markets are “running amok” and that American consumers would be “a lot better off if the FDA would allow compounding of peptides that have a demonstrated track record of safety.” Health law expert Robin Feldman of UC Law San Francisco described the move as taking these unapproved peptides out of the “back alley and into the light.”

Scientific Concerns and Divided Opinions

The panel’s endorsement represents a striking rejection of the FDA’s own scientists, who advised against the reclassification. FDA officials highlighted a “foundational challenge” in simply defining the substances, noting that the chemical composition of peptides labeled with the same name varied considerably.

“You will see many different forms,” said Russell Wesdyk, an FDA official. “We can’t create quality standards until we actually know what it is.”

Some panel members expressed serious reservations. “I’m concerned that we are responding to market induced demand rather than a decision based in solid science,” said Dr. Elizabeth Rebello, an anesthesiologist at MD Anderson Cancer Center, after casting a no vote.

Dr. Brian Lee of the USC Keck School of Medicine was more blunt: “I think this endorsement can be potentially harmful and I cannot in good conscience vote yes.”

The tension between evidence and demand was laid bare by the paradoxical outcome: Emideltide, the only peptide rejected, has the most human clinical data among the seven, while MOTS-c, which was approved, has zero published human clinical studies.

The Kennedy Factor

The vote comes after significant changes to the panel’s composition. In June 2026, eight new members were appointed to the PCAC, most with ties to the peptide industry — including physicians working for clinics and telehealth companies that promote these therapies. The FDA advisory committee meeting was the first convened under the new roster.

Secretary Kennedy has publicly embraced peptide therapies and signaled his intent to reshape FDA policy in this area. In a February 2026 appearance on the Joe Rogan podcast, he announced plans to change the regulatory status of roughly 14 peptides. Kennedy has also described himself as a “big fan” of these compounds as part of his broader “Make America Healthy Again” agenda. In an April hearing before Congress, Kennedy defended his approach to health policy, which has included efforts to overhaul FDA regulations on alternative therapies.

The HHS press secretary stated that the FDA’s goal is ensuring access to products “produced under appropriate quality standards,” pushing back on criticism about potential conflicts of interest among newly appointed panel members.

What Comes Next

The panel’s recommendation is non-binding. If the FDA moves to reclassify the peptides, it will initiate a formal rulemaking process — including a Notice of Proposed Rulemaking and a public comment period — that could take 12 to 24 months. However, Kennedy could potentially invoke special authority to make the compounds available sooner.

As of July 25, no FDA statement or Federal Register action has been published. The panel is scheduled to meet again in February 2027 to consider five additional peptides: LL-37, GHK-Cu, Melanotan II, Dihexa acetate, and PEG-MGF.

A Broader Shift in Drug Regulation

The vote represents more than a policy change for seven compounds. It signals a potential shift in how the U.S. regulates unapproved but widely used therapies, placing consumer demand and access alongside — or ahead of — traditional evidentiary standards. Critics warn this could set a precedent for bypassing the rigorous clinical trial process that underpins American drug safety. Supporters counter that the current system has failed patients by driving them toward unregulated suppliers, and that controlled compounding offers a safer middle ground.

Regardless of the outcome, the debate has highlighted a fundamental question: In an era of widespread consumer demand for wellness and longevity treatments, how should regulators balance the promise of access against the risk of unproven therapies?